Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

2.480 -0.050 (-1.98%)
Streaming Delayed Price Updated: 10:32 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
Via Investor Brand Network
Earnings Scheduled For June 28, 2023
Companies Reporting Before The Bell • General Mills (NYSE:GIS) is estimated to report quarterly earnings at $1.07 per share on revenue of $5.17 billion. 
Via Benzinga
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Eyes Advancement of Itruvone into Phase 2B Development
Via Investor Brand Network
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
From Vistagen
Via Business Wire
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Upcoming Maxim Group Healthcare Virtual Conference
Via Investor Brand Network
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
From Vistagen
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) PH80 Nasal Spray to Receive EPO Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH80 Exploratory Phase 2A Study
Via Investor Brand Network
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
Vistagen's Nasal Spray Shows Efficacy In Menopausal Hot Flashes
Vistagen Therapeutics Inc (NASDAQ: VTGN) announced that PH80, one of the Company's five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Participate in Upcoming Jefferies Global Healthcare Conference
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
From Vistagen
Via Business Wire
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split
Via Investor Brand Network
Vistagen Announces Stockholder-Approved Reverse Stock Split
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
Via Investor Brand Network
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P... 
Via Benzinga
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.82% to 32,773.27 while the NASDAQ fell 0.86% to 12,905.49. The... 
Via Benzinga
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.